AMPEL BioSolutions is a precision medicine company commercializing a development pipeline of CLIA-certified gene expression tests for blood or tissue samples that provide clinical decision support by determining disease status, identifying molecular pathway and predicting drug options. AMPEL’s technology is a cloud-based platform and hosts proprietary RNA analytic tools and machine learning algorithms covered by 25+ filed/pending patents and 90+ peer-reviewed publications. Machine learning predictions are fueled by coverage of 95% of all known genes and an exclusive curated database of >20,000 gene expression profiles with rich clinical data. Autoimmune and inflammatory diseases are the focus of our product portfolio. AMPEL is now validated and in 2023, our 1st product, the LuGENE® blood test for Lupus to predict flares and decision support for drug options. In 2023, AMPEL was ranked by Nature in the top five Precision Medicine Companies with respect to the impact of published science.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):